Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Small Cell Lung Carcinoma 10Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Cholangiocarcinoma 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Oropharyngeal Neoplasms 6Fallopian Tube Neoplasms 6Urinary Bladder Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Gallbladder Neoplasms 4Brain Neoplasms 4Adenocarcinoma of Lung 4Stomach Neoplasms 3Sarcoma 3Mouth Neoplasms 3Mesothelioma, Malignant 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Urethral Neoplasms 2Triple Negative Breast Neoplasms 2Testicular Neoplasms 2Seminoma 2Salivary Gland Neoplasms 2Recurrence 2Prostatic Neoplasms 2Peritoneal Neoplasms 2

Interventions

Gemcitabine 2Cystectomy 2Cisplatin 2transplatin 1pembrolizumab 1pegfilgrastim 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Platinum 1Chemoradiotherapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Infiltrating Bladder Urothelial Carcinoma × Platinum × Clear all
NCT02944357 2017-11-17

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Mayo Clinic

Phase NA Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡